Aims and objectives:
To establish the role of ormeloxifene in the medical management of DUB.
Materials and Methods: Hundred women with DUB enrolled in the study group and 60mg of ormeloxifene was given orally for three months twice weekly and then once weekly for next three months. The improvement was assessed with increase in the hemoglobin levels and reduction in the endometrial thickness.
Results: The mean hemoglobin level before treatment was 8.56g% and after treatment it was 11.86g% with P value of 0.00 which is very significant. The endometrial thickness before the treatment was 12.01mm and after the treatment the endometrial thickness was reduced to 8.05mm with the P value of 0.00 which is very significant.
Conclusion: Ormeloxifene is an excellent drug in the medical management of DUB with better acceptability and safety.